Navigation Links
Bayer HealthCare Provides Nearly $2.5 Million to Advance Hemophilia Research and Patient Care
Date:7/28/2011

WAYNE, N.J., July 28, 2011 /PRNewswire/ -- Bayer HealthCare today announced the 2011 recipients of the Bayer Hemophilia Awards Program (BHAP).  This year, the company has awarded nearly $2.5 million in funding to 18 recipients from 12 countries, including the U.S.  BHAP, the largest program of its kind for the hemophilia community, was created to help improve the understanding and treatment of hemophilia and related bleeding disorders.  The program also seeks to reduce the disease's impact on individuals and their communities, and support the next generation of care and treatment options worldwide for people with hemophilia.

BHAP supports research in bleeding disorders, ranging from studies to better understand inhibitor development and methods for treatment, gene therapy and joint care to the development of pediatric care models in underserved markets and hemophilia counseling.

"We're very pleased to award and congratulate these future hemophilia thought leaders for their exemplary passion, talent and expertise," said John E. Murphy, Ph.D., Director, Molecular Biology, Biologics Research, Bayer HealthCare. "BHAP is a reflection of Bayer's commitment to expanding the scientific and clinical knowledge that improves patient care."

The 2011 BHAP recipients were selected by a global committee of distinguished hemophilia clinicians, researchers and caregivers, and were honored at the BHAP award ceremony held in conjunction with the International Society of Thrombosis and Haemostasis (ISTH) Annual Meeting in Kyoto, Japan.  Among this year's winners are:

  • Dr. John Sheehan of the University of Wisconsin, for "Contribution of the heparin binding exosite to factor IX clearance and in vivo activity"
  • Dr. Carol Miao, Seattle Children's Research Institute, for "Immunimodulation to eradicate anti-factor VIII inhibitory antibodies"
  • Dr. Paris Margaritis, The Children's Hospital of
    '/>"/>

SOURCE Bayer HealthCare
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013 Fuse Science, Inc. (OTCQB: DROP), ( ... is developing new, patent-pending technologies poised to redefine how consumers ... will hold a business update teleconference and webcast for shareholders ... 2013 at 4:30 PM ET. Fuse Science, ... the call and will be joined by Rubin ...
(Date:5/17/2013)...  Sanofi (EURONEXT: SAN and NYSE: SNY ) ... , examining the selective JAK2 inhibitor SAR302503 for ... groups. The primary endpoint assessed the proportion of patients ... reported in previous trials, the most common adverse events ... be presented at an upcoming medical congress. ...
(Date:5/16/2013)... , May 17, 2013 ... and Switzerland,s Cytos Biotechnology AG today ... a Phase 1 clinical trial with their H1N1 influenza vaccine ... technology. In this first Phase 1 clinical trial, the safety ... to protect against H1N1 influenza infection will be evaluated. ...
Breaking Medicine Technology:Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6
... MONTVALE, N.J., Feb. 19 Memory,Pharmaceuticals Corp. ... plans to,conduct a clinical study of MEM 3454, ... biomarkers of schizophrenia, P50 sensory gating and,mismatch negativity, ... formulation and manufacturing activities for MEM 3454, will,be ...
... seven-year, international,study published today finds that some alternative ... better choices for managing,most common neck pain than ... best options for relief are exercises, education, neck,mobilization, ... Therapies such as neck collars and ultrasound are ...
Cached Medicine Technology:Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia 2Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia 3Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia 4Seven-Year Neck Pain Study Sheds Light on Best Care 2Seven-Year Neck Pain Study Sheds Light on Best Care 3
(Date:5/19/2013)... Healthcare leaders will gather at the ... Walt Disney World Swan and Dolphin in Orlando, Fla., ... care delivery and healthcare reform and implementation. , “Reform ... markets, with consolidation, efficiency and reduced payments ... Ebert, Amerinet president and CEO. “There is a real ...
(Date:5/19/2013)... 19, 2013 The muscles in the ... functionality and one of the biggest and most significant ... system. The peripheral system comprises of peripheral nerves that ... These nerves ensure that the limbs and hands, as ... these nerves get damaged due to trauma or physical ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 These ... for US, UK, Spain, Japan, Italy, Germany and ... the molecular diagnostics laboratory practice, as well as ... with significant market impact during the next five ... probe and biochip technologies, test formats, detection methodologies, ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Farming methods ... seed in the ground 10,000 years ago. Most recently, ... farm productivity by using genetically engineered seeds and by ... seeing a backlash to these techniques due to the ... chemicals and a corresponding surge in interest in organic, ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Agora Health Limited ... that covers guides on how to increase memory power ... memory training method that helps people re-new their entire health ... and beat depression caused by a fatigued mind. In addition, ... razor sharp for a lifetime. The author claimed that this ...
Breaking Medicine News(10 mins):Health News:Healthcare Leaders Gather at 2013 Amerinet Member Conference to Share New Ways to Reduce Costs and Enhance Care Delivery 2Health News:Ultimate Neuropathy Support System Launched by Neuracel - Reaching New Heights in Herbal Medication for Peripheral Neuropathy 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 2Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 3Health News:How To Increase Memory Power | How “Agora Health Limited” Helps People Improve Their Memory Naturally And Effectively – Health Review 2
... of Global Breast Cancer Movement Continues Unprecedented Investment ... Committed to caring for those coping with ... of the disease, Susan G. Komen for the ... announced $60 million in research grants to U.S. ...
... Food Experts HARRY EASTWOOD, ALLISON FISHMAN ... Tiger Aspect Productions Lose the Bulge...but Still ... to have your cake and eat it, too? Lifetime ... that offers viewers the skills and the confidence to give ...
... Lincoln Financial Group (NYSE: LNC ) today ... on its group long-term disability (LTD) insurance product. Lincoln already ... market and -- with the addition of this optional benefit ... insureds overcome family care cost concerns as they try to ...
... REDUCED ETS EXPOSURE , Environmental tobacco smoke (ETS) ... children. However, a new study shows that reducing ... of Alabama researchers followed 240 children with asthma ... asthma therapy. No smoking cessation counseling or ETS ...
... County Health Authority has begun using a web-based ... and enrollment of prospective Medicaid recipients. The new ... health care technology firm based in Norwalk, CT. ... patients to the right assistance program by facilitating ...
... 7 MedPage Today , the only breaking medical ... the challenge posed by the downsizing of newspapers and other ... Today is not only standing firm, but is investigating ... C.E.O. of MedPage Today . The full pledge is ...
Cached Medicine News:Health News:Susan G. Komen For The Cure(R) to Invest $60 Million in Research to Accelerate Breast Cancer Cures, Eliminate Disparities, Improve Diagnoses 2Health News:Susan G. Komen For The Cure(R) to Invest $60 Million in Research to Accelerate Breast Cancer Cures, Eliminate Disparities, Improve Diagnoses 3Health News:Susan G. Komen For The Cure(R) to Invest $60 Million in Research to Accelerate Breast Cancer Cures, Eliminate Disparities, Improve Diagnoses 4Health News:Susan G. Komen For The Cure(R) to Invest $60 Million in Research to Accelerate Breast Cancer Cures, Eliminate Disparities, Improve Diagnoses 5Health News:Cook Yourself Thin With Lifetime Television as All-New Culinary Series Teaches Viewers How to Prepare Skinny Alternatives to Their Favorite Foods 2Health News:Cook Yourself Thin With Lifetime Television as All-New Culinary Series Teaches Viewers How to Prepare Skinny Alternatives to Their Favorite Foods 3Health News:Cook Yourself Thin With Lifetime Television as All-New Culinary Series Teaches Viewers How to Prepare Skinny Alternatives to Their Favorite Foods 4Health News:Lincoln Financial Group Announces Family Care Reimbursement Benefit Rider on LTD Policies 2Health News:Lincoln Financial Group Announces Family Care Reimbursement Benefit Rider on LTD Policies 3Health News:Lincoln Financial Group Announces Family Care Reimbursement Benefit Rider on LTD Policies 4Health News:Journal Chest: April news briefs 2Health News:Health Authority Offers Expedient, Web-Based Medicaid Enrollment Service 2Health News:Health Authority Offers Expedient, Web-Based Medicaid Enrollment Service 3Health News:MedPage Today Pledges to Maintain and Expand News Coverage in 2009 2
... for the mid- to high-volume lab, the ... can reduce time-consuming manual tasks by as ... performs random access, STAT, HCFA panels and ... including Stat chemistries, General chemistries, TDMs, DATs, ...
... on-board capacity of 57 assays ... 146 tests, the CX1000 PRO ... so you can maximize your ... workload. The CX1000 PRO creates ...
When it comes to providing speed, accuracy and menu flexibility, the SYNCHRON CX5 PRO has it all. The state-of-the-art CX5 PRO starts with the wide SYNCHRON chemistry menu to create the ideal full-se...
The leading fully automated system for plasma protein determinations. Third generation nephelometer combines reliability with highly cost-effective performance....
Medicine Products: